ICU Medical (ICUI)
Market Price (7/22/2026): $158.91 | Market Cap: $3.9 BilSector: Health Care | Industry: Health Care Supplies
ICU Medical (ICUI)
Market Price (7/22/2026): $158.91Market Cap: $3.9 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 38% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Oncology Treatments, Geriatric Care, Show more. | Trading close to highsDist 52W High is -2.1% Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -79% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 40x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x, P/EPrice/Earnings or Price/(Net Income) is 85x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.9%, Rev Chg QQuarterly Revenue Change % is -12% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% Key risksICUI key risks include [1] an FDA warning letter and potential legal action over unauthorized modifications to its infusion pumps, Show more. |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Oncology Treatments, Geriatric Care, Show more. |
| Trading close to highsDist 52W High is -2.1% |
| Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -79% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 40x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x, P/EPrice/Earnings or Price/(Net Income) is 85x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.9%, Rev Chg QQuarterly Revenue Change % is -12% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% |
| Key risksICUI key risks include [1] an FDA warning letter and potential legal action over unauthorized modifications to its infusion pumps, Show more. |
Qualitative Assessment
AI Analysis | Feedback
ICU Medical (ICUI) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Earnings Beat and Reaffirmed Full-Year Guidance.
ICU Medical exceeded analyst expectations for its fiscal Q1 2026, which ended March 31, 2026. The company reported adjusted earnings per share (EPS) of $1.97, significantly beating the consensus estimate of $1.78 by $0.19, or 17.96%. This strong performance was accompanied by revenue of $525.77 million, surpassing analyst estimates of $520.65 million. Management further boosted investor confidence by reaffirming its full-year fiscal 2026 EPS guidance of $7.75 to $8.45 and adjusted EBITDA guidance of $400 million to $430 million.
2. Multiple Analyst Upgrades and Increased Price Targets.
Following the positive earnings report and outlook, several prominent financial firms upgraded ICU Medical's stock rating and increased their price targets. Jefferies Financial Group raised the stock to a "strong-buy" rating, and Wall Street Zen upgraded it to a "buy" rating in May 2026. In June 2026, BTIG Research initiated coverage with a "buy" rating and a $170 price target, while Needham also raised its rating to "Buy" with a $165 target. Zacks Research further upgraded the stock to a "strong-buy" in July 2026. The collective analyst sentiment shifted to generally positive, with a consensus "Buy" rating and an average target price of $168.40, indicating perceived upside potential.
Show more
ICU Medical (ICUI) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q1 2026 Earnings Beat and Reaffirmed Full-Year Guidance.
ICU Medical exceeded analyst expectations for its fiscal Q1 2026, which ended March 31, 2026. The company reported adjusted earnings per share (EPS) of $1.97, significantly beating the consensus estimate of $1.78 by $0.19, or 17.96%. This strong performance was accompanied by revenue of $525.77 million, surpassing analyst estimates of $520.65 million. Management further boosted investor confidence by reaffirming its full-year fiscal 2026 EPS guidance of $7.75 to $8.45 and adjusted EBITDA guidance of $400 million to $430 million.
2. Multiple Analyst Upgrades and Increased Price Targets.
Following the positive earnings report and outlook, several prominent financial firms upgraded ICU Medical's stock rating and increased their price targets. Jefferies Financial Group raised the stock to a "strong-buy" rating, and Wall Street Zen upgraded it to a "buy" rating in May 2026. In June 2026, BTIG Research initiated coverage with a "buy" rating and a $170 price target, while Needham also raised its rating to "Buy" with a $165 target. Zacks Research further upgraded the stock to a "strong-buy" in July 2026. The collective analyst sentiment shifted to generally positive, with a consensus "Buy" rating and an average target price of $168.40, indicating perceived upside potential.
3. Credit Rating Upgrade Reflecting Improved Financial Leverage.
Moody's Ratings upgraded ICU Medical's corporate family rating to Ba3 from B1 on June 17, 2026, assigning a stable outlook. This upgrade was driven by Moody's expectations that the company's adjusted debt to EBITDA leverage would remain below 4.0x over the next 12 months. This improvement is anticipated due to low single-digit revenue growth, robust free cash flow generation (projected over $100 million annually), and continued debt reduction efforts. Moody's also acknowledged ICU Medical's progress in executing cost improvement initiatives and operational efficiencies that are expected to support margin expansion. Fitch Ratings also revised ICU Medical's outlook to Stable from Negative on March 31, 2026, affirming its IDR at 'BB', based on expectations of declining leverage and margin improvement.
4. Significant Investment in IV Solutions Manufacturing Expansion.
The Otsuka ICU Medical LLC, a joint venture, announced on July 9, 2026, plans for an over $500 million expansion of its IV solutions manufacturing operations in Austin, Texas. This initiative includes adding a new 500,000-square-foot facility and upgrading the existing 700,000-square-foot site. The expansion aims to enhance North American supply resiliency for IV solutions and accelerate the development of non-DEHP IV solutions, aligning with evolving legislative requirements. This strategic investment is seen as a major milestone for the joint venture, promising long-term benefits for the company's market position and product offerings.
5. Favorable Broader Healthcare Sector Trends.
The healthcare services sector experienced a significant rebound in fiscal Q2 2026, outperforming the S&P 500 and Nasdaq. This positive trend was primarily fueled by the Centers for Medicare & Medicaid Services' (CMS) final 2027 Medicare Advantage rate notice, which presented an effective increase of approximately 5%, a substantial improvement from earlier projections. Additionally, Q1 earnings reports from major payers provided evidence of cooling medical cost trends. This supportive macroeconomic environment created tailwinds for medical device companies like ICU Medical, contributing to the positive sentiment around its stock performance.
Show less
Stock Movement Drivers
Fundamental Drivers
The 22.9% change in ICUI stock from 3/31/2026 to 7/21/2026 was primarily driven by a 6449.2% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.15 | 158.77 | 22.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,231 | 2,157 | -3.3% |
| Net Income Margin (%) | 0.0% | 2.1% | 6449.2% |
| P/E Multiple | 4,355.8 | 84.8 | -98.1% |
| Shares Outstanding (Mil) | 25 | 25 | -0.3% |
| Cumulative Contribution | 22.9% |
Market Drivers
3/31/2026 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ICUI | 22.9% | |
| Market (SPY) | 15.1% | 30.2% |
| Sector (XLV) | 9.3% | 42.5% |
Fundamental Drivers
The 11.3% change in ICUI stock from 12/31/2025 to 7/21/2026 was primarily driven by a 20.1% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 142.67 | 158.77 | 11.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,320 | 2,157 | -7.0% |
| P/S Multiple | 1.5 | 1.8 | 20.1% |
| Shares Outstanding (Mil) | 25 | 25 | -0.3% |
| Cumulative Contribution | 11.3% |
Market Drivers
12/31/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ICUI | 11.3% | |
| Market (SPY) | 10.0% | 48.0% |
| Sector (XLV) | 3.9% | 42.7% |
Fundamental Drivers
The 20.1% change in ICUI stock from 6/30/2025 to 7/21/2026 was primarily driven by a 36.0% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 132.15 | 158.77 | 20.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,420 | 2,157 | -10.9% |
| P/S Multiple | 1.3 | 1.8 | 36.0% |
| Shares Outstanding (Mil) | 25 | 25 | -0.9% |
| Cumulative Contribution | 20.1% |
Market Drivers
6/30/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ICUI | 20.1% | |
| Market (SPY) | 22.1% | 34.9% |
| Sector (XLV) | 20.4% | 40.1% |
Fundamental Drivers
The -10.9% change in ICUI stock from 6/30/2023 to 7/21/2026 was primarily driven by a -6.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 178.19 | 158.77 | -10.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,306 | 2,157 | -6.5% |
| P/S Multiple | 1.9 | 1.8 | -1.8% |
| Shares Outstanding (Mil) | 24 | 25 | -3.0% |
| Cumulative Contribution | -10.9% |
Market Drivers
6/30/2023 to 7/21/2026| Return | Correlation | |
|---|---|---|
| ICUI | -10.9% | |
| Market (SPY) | 74.8% | 42.6% |
| Sector (XLV) | 26.4% | 37.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ICUI Return | 11% | -34% | -37% | 56% | -8% | 10% | -27% |
| Peers Return | 5% | -25% | -2% | -12% | -7% | 3% | -35% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| ICUI Win Rate | 42% | 25% | 33% | 50% | 25% | 71% | |
| Peers Win Rate | 48% | 42% | 48% | 53% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| ICUI Max Drawdown | -16% | -45% | -61% | -17% | -37% | -27% | |
| Peers Max Drawdown | -20% | -38% | -30% | -25% | -31% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BAX, BDX, TFX, EW, MDT. See ICUI Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/21/2026 (YTD)
How Low Can It Go
| Event | ICUI | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.9% | -9.5% |
| % Gain to Breakeven | 112.4% | 10.5% |
| Time to Breakeven | 308 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -15.5% | -6.7% |
| % Gain to Breakeven | 18.3% | 7.1% |
| Time to Breakeven | 45 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -26.0% | -33.7% |
| % Gain to Breakeven | 35.1% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.3% | 13.9% |
| Time to Breakeven | 186 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -16.3% | -17.9% |
| % Gain to Breakeven | 19.5% | 21.8% |
| Time to Breakeven | 45 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -12.0% | -15.4% |
| % Gain to Breakeven | 13.6% | 18.2% |
| Time to Breakeven | 35 days | 125 days |
In The Past
ICU Medical's stock fell -2.7% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ICUI | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.9% | -9.5% |
| % Gain to Breakeven | 112.4% | 10.5% |
| Time to Breakeven | 308 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -26.0% | -33.7% |
| % Gain to Breakeven | 35.1% | 50.9% |
| Time to Breakeven | 31 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.3% | 13.9% |
| Time to Breakeven | 186 days | 62 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -39.8% | -53.4% |
| % Gain to Breakeven | 66.0% | 114.4% |
| Time to Breakeven | 316 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -24.6% | -8.6% |
| % Gain to Breakeven | 32.7% | 9.5% |
| Time to Breakeven | 717 days | 47 days |
In The Past
ICU Medical's stock fell -2.7% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About ICU Medical (ICUI)
ICU Medical, Inc. (ICUI) is a global medical technology company that develops, manufactures, and sells a comprehensive range of medical devices primarily used in infusion therapy and critical care applications. The company's mission is to enhance patient safety and clinical outcomes across various healthcare environments by providing innovative solutions.
The company's infusion therapy products include needlefree connectors (e.g., MicroClave, NanoClave), disinfecting caps (e.g., SwabCap), and specialized hemodialysis connectors (e.g., Tego, ClearGuard HD). ICU Medical also offers closed system transfer devices (e.g., ChemoClave, ChemoLock) and compounding systems (e.g., Diana) for the safe handling of hazardous drugs. Additionally, it provides a full line of IV therapy solutions, diluents, and irrigation products, alongside smart infusion pumps like the Plum 360 and LifeCare PCA, complemented by medication safety software such as ICU Medical MedNet for integrated medication management.
In the critical care sector, ICUI supplies advanced hemodynamic monitoring systems (e.g., Cogent, CardioFlo), various cardiac output and venous oximetry catheters, blood pressure transducers (e.g., Transpac), and closed blood sampling and conservation systems (e.g., SafeSet). These critical care products are essential for monitoring and managing acutely ill patients. ICU Medical primarily serves acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities.
AI Analysis | Feedback
- A specialized Baxter International focused on IV therapy, smart infusion pumps, and critical care monitoring for hospitals.
- Like Becton Dickinson (BD), but concentrated specifically on advanced IV medication delivery, infusion safety software, and critical care monitoring systems for healthcare facilities.
AI Analysis | Feedback
Infusion Therapy Devices
Develops various products including needlefree connectors (MicroClave, NanoClave), catheter patency devices, disinfecting caps (SwabCap, SwabTip), and hemodialysis connectors (Tego, ClearGuard HD).
Hazardous Drug Management Systems
Offers closed system transfer devices (ChemoClave, ChemoLock) and the Diana hazardous drug compounding system for the safe handling and preparation of hazardous medications.
IV Solutions and Diluents
Provides a range of intravenous solutions such as sodium chloride, dextrose, balanced electrolytes, and sterile water for hydration and medication dilution.
Irrigation Solutions
Supplies various irrigation solutions including sodium chloride, sterile water, and physiologic solutions, available in flexible containers and pour bottles.
Infusion Pumps
Manufactures infusion pumps under the Plum 360 and LifeCare PCA brands for controlled delivery of fluids, medications, and nutrients.
IV Medication Safety Software
Offers ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital IT systems for enhanced safety and workflow.
Critical Care Monitoring Systems
Includes hemodynamic monitoring systems (Cogent 2-in-1, CardioFlo), cardiac output monitoring catheters, venous oximetry catheters, and blood pressure transducers.
Blood Sampling and Conservation Systems
Provides SafeSet closed blood sampling and conservation systems designed for efficient and safe blood management.
Professional Services
Offers related professional services to support the implementation, integration, and optimization of its medical devices and software solutions.
AI Analysis | Feedback
Major Customers of ICU Medical (ICUI)
ICU Medical, Inc. primarily sells its products to other companies and organizations within the healthcare sector. Based on the company description, its major customers include:- Acute care hospitals
- Wholesalers
- Ambulatory clinics
- Alternate site facilities, which encompass outpatient clinics, home health care providers, and long-term care facilities
AI Analysis | Feedback
AI Analysis | Feedback
Vivek Jain, Chairman & Chief Executive Officer
Mr. Jain joined ICU Medical in February 2014 as Chairman and Chief Executive Officer. Prior to his role at ICU Medical, he was President of the Procedural Solutions division at CareFusion Corporation, where he was responsible for a significant portfolio of medical disposables products. His career also includes leadership positions as Executive Vice President of Strategy and Corporate Development at Cardinal Health, and senior roles at Philips Medical Systems. Earlier in his career, he spent twelve years at J.P. Morgan, ultimately serving as Co-Head of Global Healthcare Investment Banking. Mr. Jain currently serves as an Independent Director for Envista Holdings Corp.Brian Bonnell, Chief Financial Officer and Treasurer
Mr. Bonnell has served as ICU Medical's Chief Financial Officer and Treasurer since March 2020. Before this, he was the company's Corporate Vice President, Finance, from May 2018 to March 2020. His prior experience includes serving as Treasurer and Head of Financial Planning and Analysis at Alere Inc. from May 2015 to December 2017. Before joining Alere, Mr. Bonnell held various financial roles at CareFusion Corporation, including Senior Vice President, Tax and Treasurer.Daniel Woolson, President
Mr. Woolson has held the position of Corporate Vice President and General Manager, Infusion Systems at ICU Medical since February 2017. His career includes various senior management and consulting roles at notable companies such as Vyaire, BD, CareFusion, Cardinal Health, and McKinsey & Company, spanning from 1999 to 2016.Christian Voigtlander, Chief Operating Officer
Mr. Voigtlander has served as ICU Medical's Chief Operating Officer since January 2018. From February 2017 to January 2018, he was the Corporate Vice President, Business Development and General Manager, Infusion Solutions. Prior to May 2015, Mr. Voigtlander held various positions at CareFusion, where his last role was Senior Vice President, Business Development and Strategy.Virginia Sanzone, Corporate Vice President, General Counsel and Secretary
Ms. Sanzone has been ICU Medical's Corporate Vice President, General Counsel and Secretary, as well as Compliance Officer, since January 2018. Before this, she served as the company's Vice President, General Counsel from August 2015 to January 2018. Her experience before joining ICU Medical includes various roles at CareFusion, where she most recently served as Senior Vice President, Associate General Counsel - Business Segments & Americas.AI Analysis | Feedback
-
Regulatory Compliance and Product Liability: As a developer and manufacturer of medical devices for infusion therapy and critical care, ICU Medical is subject to extensive and evolving regulations from health authorities worldwide. This includes stringent requirements for product development, manufacturing processes, marketing, and post-market surveillance. Non-compliance could lead to product recalls, regulatory fines, manufacturing suspensions, or even the inability to market certain products. Furthermore, the nature of their products, used in critical patient care, exposes the company to significant product liability risks, where device malfunctions or safety concerns could result in costly litigation, reputational damage, and adverse effects on sales.
-
Intense Competition and Technological Obsolescence: The medical device market, particularly in infusion therapy and critical care, is highly competitive. ICU Medical faces competition from a range of companies, including larger, more diversified medical technology firms. This competition can lead to pricing pressures, demands for increased innovation, and challenges in maintaining market share. Additionally, the rapid pace of technological advancements in healthcare means that ICU Medical's existing products could become obsolete if the company fails to continually innovate and introduce new, more advanced solutions that meet evolving clinical needs and integration requirements, such as those related to electronic health records and connected systems.
-
Healthcare Cost Containment and Reimbursement Pressures: ICU Medical's primary customers are acute care hospitals, ambulatory clinics, and other healthcare facilities. These customers are increasingly operating under significant pressure to reduce costs due to evolving healthcare reimbursement models, government healthcare reforms, and the general trend towards cost containment. This environment can lead to hospitals demanding lower prices for medical devices, delaying capital expenditures, or favoring less expensive alternatives, thereby negatively impacting ICU Medical's sales volumes and profit margins.
AI Analysis | Feedback
The rise of highly accurate and comprehensive non-invasive critical care monitoring technologies poses a clear emerging threat to ICU Medical's portfolio of invasive critical care products. These include their Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems, TDQ and OptiQ cardiac output monitoring catheters, TriOx venous oximetry catheters, and Transpac blood pressure transducers. As non-invasive solutions advance in accuracy and adoption, they could reduce the demand for traditional invasive monitoring devices by offering reduced patient risk, discomfort, and healthcare costs, representing a paradigm shift similar to past disruptions.
AI Analysis | Feedback
AI Analysis | Feedback
For ICU Medical (ICUI), several key drivers are expected to fuel future revenue growth over the next 2-3 years:
- International Expansion: ICU Medical is focusing on geographic expansion, particularly in emerging markets, to leverage its expanded scale after the Smiths Medical acquisition. This strategy includes targeting high-growth regions like EMEA, APAC, Latin America, the Middle East, and Southeast Asia, optimizing sales channels, and broadening distribution networks to reach new and underserved customer bases.
- Product Innovation and Portfolio Diversification: The company is investing in research and development to drive innovation and expand its product offerings beyond core infusion therapy. Specific initiatives include prioritizing next-generation infusion pumps, expanding the NeutraClear and MicroClave lines, upgrading oncology Closed System Transfer Devices (CSTD) like ChemoLock, and growing its presence in temperature management and respiratory care through product refresh cycles scheduled for 2025–2026.
- Growth in Core Consumables and IV Systems Businesses: The consumables business, particularly in oncology, has been a strong performer, with high single-digit growth observed in infusion consumables, oncology, and tracheostomy product lines. Similarly, the IV Systems business has demonstrated double-digit growth in LVP (Large Volume Parenteral) revenue, driven by increased utilization and competitive wins. Management anticipates mid-single-digit sales growth for these segments in the medium term.
- Leveraging Smiths Medical Acquisition for Synergies and Installed Base Recovery: The strategic acquisition of Smiths Medical aims to enhance ICU Medical's market position, expand its product portfolio, and strengthen its global presence. A key focus is on completing the integration of Smiths Medical by 2025, which includes SKU and platform rationalization, consolidated manufacturing, and ERP harmonization to improve gross margins and service levels. Additionally, regaining market share in large capital fleets, such as Medfusion and CADD pumps, is central to driving high-margin disposable pull-through and restoring recurring revenue growth.
AI Analysis | Feedback
Share Repurchases
ICU Medical has not made significant share repurchases over the last 3-5 years. The treasury stock values observed in financial reports suggest minor adjustments, likely related to employee stock plans, rather than a material share repurchase program.
Share Issuance
- The company's issued and outstanding shares increased from 24,518 at December 31, 2024, to 24,688 at December 31, 2025.
- Additional paid-in capital increased to $1,451,146 in 2025 from $1,412,118 in 2024, and from $1,366,493 in 2023 to $1,412,118 in 2024, indicating share issuances.
Inbound Investments
- In Q2 2025, ICU Medical received $200 million in proceeds from the formation of the Otsuka ICU Medical JV, which was entirely used for debt repayment.
Outbound Investments
- On May 1, 2025, ICU Medical disposed of its IV Solutions business through the creation of the Otsuka ICU Medical JV.
- ICU Medical holds a 40% equity investment in the Otsuka ICU Medical JV, leading to a significant increase in investments in unconsolidated affiliates from approximately $3 million in 2024 to $131.6 million in 2025.
Capital Expenditures
- Capital expenditures were $24 million in 2021, $15 million in 2022, $20 million in 2023, and $29 million in 2024.
- For 2025, estimated capital expenditures were in the range of $90 million to $110 million.
- Capital expenditures in 2025 were focused on general maintenance, capacity expansion at facilities, and the placement of revenue-generating infusion pumps with customers internationally.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 109.78 |
| Mkt Cap | 27.3 |
| Rev LTM | 8,812 |
| Op Inc LTM | 963 |
| FCF LTM | 902 |
| FCF 3Y Avg | 650 |
| CFO LTM | 1,305 |
| CFO 3Y Avg | 1,014 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 7.5% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | -2.4% |
| Op Inc Chg 3Y Avg | 7.0% |
| Op Mgn LTM | 11.7% |
| Op Mgn 3Y Avg | 13.5% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 17.6% |
| CFO/Rev 3Y Avg | 16.9% |
| FCF/Rev LTM | 13.3% |
| FCF/Rev 3Y Avg | 12.7% |
Price Behavior
| Market Price | $158.77 | |
| Market Cap ($ Bil) | 3.9 | |
| First Trading Date | 03/31/1992 | |
| Distance from 52W High | -2.1% | |
| 50 Days | 200 Days | |
| DMA Price | $140.51 | $137.41 |
| DMA Trend | up | up |
| Distance from DMA | 13.0% | 15.5% |
| 3M | 1YR | |
| Volatility | 36.7% | 38.5% |
| Downside Capture | 7.35 | 89.87 |
| Upside Capture | 98.94 | 101.88 |
| Correlation (SPY) | 29.1% | 34.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.46 | 0.66 | 0.84 | 1.29 | 1.07 | 1.20 |
| Up Beta | 0.18 | 0.95 | 1.38 | 1.42 | 1.33 | 1.39 |
| Down Beta | 0.93 | 1.46 | 0.84 | 1.35 | 0.92 | 0.85 |
| Up Capture | 92% | 97% | 64% | 113% | 95% | 120% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 10 | 22 | 30 | 59 | 120 | 361 |
| Down Capture | -3% | -43% | 38% | 127% | 107% | 108% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 11 | 19 | 33 | 66 | 131 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | 29.8% | 38.4% | 0.76 | - |
| Sector ETF (XLV) | 23.2% | 15.8% | 1.13 | 39.0% |
| Equity (SPY) | 20.3% | 12.6% | 1.19 | 34.3% |
| Gold (GLD) | 21.6% | 28.1% | 0.69 | 10.7% |
| Commodities (DBC) | 31.4% | 19.1% | 1.30 | -24.7% |
| Real Estate (VNQ) | 15.0% | 14.0% | 0.76 | 44.7% |
| Bitcoin (BTCUSD) | -44.6% | 42.9% | -1.25 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | -4.0% | 41.2% | 0.02 | - |
| Sector ETF (XLV) | 6.1% | 15.0% | 0.22 | 40.2% |
| Equity (SPY) | 12.9% | 17.1% | 0.58 | 42.4% |
| Gold (GLD) | 17.3% | 18.4% | 0.76 | 11.0% |
| Commodities (DBC) | 8.9% | 19.5% | 0.35 | 4.9% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 44.1% |
| Bitcoin (BTCUSD) | 14.9% | 53.4% | 0.46 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ICUI | |
|---|---|---|---|---|
| ICUI | 3.7% | 37.6% | 0.21 | - |
| Sector ETF (XLV) | 9.9% | 16.6% | 0.48 | 39.7% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 39.7% |
| Gold (GLD) | 11.2% | 16.1% | 0.57 | 5.8% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 8.5% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 34.8% |
| Bitcoin (BTCUSD) | 58.7% | 66.2% | 0.99 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 2.7% | -0.1% | 11.7% |
| 2/19/2026 | 4.9% | 0.7% | -16.3% |
| 11/6/2025 | 8.1% | 6.8% | 9.9% |
| 8/7/2025 | -13.1% | -13.9% | 0.5% |
| 5/8/2025 | -3.2% | -1.6% | -4.6% |
| 2/27/2025 | -2.3% | -5.0% | -6.4% |
| 11/12/2024 | -1.8% | -4.7% | -7.0% |
| 8/7/2024 | 24.3% | 21.5% | 33.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 11 |
| # Negative | 13 | 15 | 13 |
| Median Positive | 5.3% | 6.8% | 6.8% |
| Median Negative | -4.9% | -6.6% | -8.2% |
| Max Positive | 24.3% | 21.5% | 33.3% |
| Max Negative | -17.3% | -19.6% | -18.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 2.7% | -0.1% | 11.7% |
| 2/19/2026 | 4.9% | 0.7% | -16.3% |
| 11/6/2025 | 8.1% | 6.8% | 9.9% |
| 8/7/2025 | -13.1% | -13.9% | 0.5% |
| 5/8/2025 | -3.2% | -1.6% | -4.6% |
| 2/27/2025 | -2.3% | -5.0% | -6.4% |
| 11/12/2024 | -1.8% | -4.7% | -7.0% |
| 8/7/2024 | 24.3% | 21.5% | 33.3% |
| 5/7/2024 | -1.1% | 3.4% | 6.5% |
| 2/27/2024 | 5.3% | -4.0% | -3.7% |
| 11/6/2023 | -17.3% | -19.6% | -15.4% |
| 8/7/2023 | -16.6% | -16.7% | -18.1% |
| 5/8/2023 | 13.6% | 8.2% | 4.3% |
| 2/27/2023 | -3.9% | -9.2% | -12.2% |
| 11/7/2022 | 2.4% | 11.7% | 7.4% |
| 8/8/2022 | -11.6% | -6.6% | -12.1% |
| 5/9/2022 | -8.2% | -10.2% | -12.7% |
| 2/24/2022 | 5.7% | 10.8% | 4.1% |
| 11/3/2021 | 0.1% | -0.4% | -8.2% |
| 8/4/2021 | 0.9% | -1.1% | 6.8% |
| 5/6/2021 | -5.2% | -7.3% | -3.8% |
| 2/25/2021 | -4.9% | -9.2% | -3.8% |
| 11/5/2020 | -0.0% | 3.6% | 4.4% |
| 8/10/2020 | 8.1% | 3.1% | 9.1% |
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 11 |
| # Negative | 13 | 15 | 13 |
| Median Positive | 5.3% | 6.8% | 6.8% |
| Median Negative | -4.9% | -6.6% | -8.2% |
| Max Positive | 24.3% | 21.5% | 33.3% |
| Max Negative | -17.3% | -19.6% | -18.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Insider Activity
Updated 5/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Woolson, Daniel | President | Direct | Sell | 5222026 | 132.21 | 2,123 | 280,685 | 2,971,980 | Form |
| 2 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 5152026 | 124.08 | 2,447 | 303,624 | 2,414,597 | Form |
| 3 | Greenberg, David C | Direct | Sell | 5132026 | 122.91 | 2,424 | 297,934 | 978,364 | Form | |
| 4 | Woolson, Daniel | VP, GM-Infusion Capital | Direct | Sell | 11252025 | 152.35 | 2,897 | 441,364 | 1,721,123 | Form |
| 5 | Finney, Elisha W | Direct | Sell | 11112025 | 140.42 | 1,285 | 180,440 | 560,978 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Woolson, Daniel | President | Direct | Sell | 5222026 | 132.21 | 2,123 | 280,685 | 2,971,980 | Form |
| 2 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 5152026 | 124.08 | 2,447 | 303,624 | 2,414,597 | Form |
| 3 | Greenberg, David C | Direct | Sell | 5132026 | 122.91 | 2,424 | 297,934 | 978,364 | Form | |
| 4 | Woolson, Daniel | VP, GM-Infusion Capital | Direct | Sell | 11252025 | 152.35 | 2,897 | 441,364 | 1,721,123 | Form |
| 5 | Finney, Elisha W | Direct | Sell | 11112025 | 140.42 | 1,285 | 180,440 | 560,978 | Form | |
| 6 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 11112025 | 142.34 | 930 | 132,381 | 776,634 | Form |
| 7 | Greenberg, David C | Direct | Buy | 8272025 | 126.42 | 1,200 | 151,698 | 1,006,265 | Form | |
| 8 | Jain, Vivek | Chairman and CEO | Direct | Buy | 8142025 | 112.84 | 21,929 | 2,474,375 | 14,685,456 | Form |
| 9 | Sanzone, Virginia Ruth | VP, General Counsel | Direct | Sell | 5302025 | 133.62 | 700 | 93,537 | 853,325 | Form |
| 10 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5282025 | 128.50 | 4,985 | 640,576 | 782,313 | Form |
| 11 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5282025 | 131.00 | 4,945 | 647,795 | 722,203 | Form |
| 12 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5232025 | 130.00 | 4,959 | 644,670 | 637,390 | Form |
| 13 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5232025 | 130.03 | 4,959 | 644,832 | 560,051 | Form |
| 14 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5212025 | 133.00 | 4,917 | 653,961 | 493,563 | Form |
| 15 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5212025 | 137.11 | 4,871 | 667,879 | 421,349 | Form |
| 16 | Finney, Elisha W | Direct | Sell | 5202025 | 138.92 | 600 | 83,353 | 451,771 | Form | |
| 17 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5192025 | 138.00 | 5,555 | 766,614 | 329,693 | Form |
| 18 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5192025 | 140.00 | 5,555 | 777,700 | 334,460 | Form |
| 19 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5152025 | 135.55 | 5,555 | 752,977 | 323,828 | Form |
| 20 | Sousa, Ben | Chief Information Officer | Direct | Sell | 5152025 | 137.36 | 2,000 | 274,714 | 65,794 | Form |
| 21 | Voigtlander, Christian B | Chief Operating Officer | Direct | Sell | 5152025 | 138.65 | 5,556 | 770,324 | 331,228 | Form |
| 22 | Greenberg, David C | Direct | Sell | 5132025 | 143.66 | 1,942 | 278,992 | 971,158 | Form |
Investor Activity (13F)
Updated Jul 22, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.